Smell: Integrating neurodegeneration and autoimmunity A personal view;Olfacto: Uma visão pessoal integrando neurodege neração e autoimunidade

Acta Reumatologica Portuguesa

Volumn 34, Issue 2, 2009, Pages 190-196

  Moscavitch, Samuel Datum ^a,b   Szyper Kravitz, Martine ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Autoimmunity; Depression; Neurodegenerative diseases; Smell

Indexed keywords

ANIMAL; AUTOIMMUNE DISEASE; DEGENERATIVE DISEASE; HUMAN; IMMUNOLOGY; ODOR; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; NEURODEGENERATIVE DISEASES; SMELL;

EID: 67650142901     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Lévy P. O Fogo Libertador. 2 ed. São Paulo: Iluminuras; 2000.
2. Jellinek JS. Psychodynamic odor effects and their mechanisms. Cosmet Toilet 1997;112:61-71.
3. Li W, Howard JD, Parrish TB, Gottfried JA. Aversive learning enhances perceptual and cortical discrimination of indiscriminable odor cues. Science 2008;319:1842-5.
4. Savic I. Imaging of brain activation by odorants in humans. Curr Opin Neurobiol 2002;12:455-61.
5. Mallon EB, Brockmann A, Schmid-Hempel P. Immune response inhibits associative learning in insects. Proc Biol Sci 2003;270:2471-3.
6. Diego MA, Jones NA, Field T, et al. Aromatherapy positively affects mood, EEG patterns of alertness and math computations. Int J Neurosci 1998;96:217-24.
7. Kiecolt-Glaser JK, Graham JE, Malarkey WB, Porter K, Lemeshow S, Glaser R. Olfactory influences on mood and autonomic, endocrine, and immune function. Psychoneuroendocrinology 2008;33:328-39.
8. Wang J, Eslinger PJ, Smith MB, Yang QX. Functional magnetic resonance imaging study of human olfaction and normal aging. J Gerontol A Biol Sci Med Sci 2005;60:510-4.
9. Klein D, Brown TS. Exploratory behavior and spontaneous alternation in blind and anosmic rats. J Comp Physiol Psychol 1969;68:107-10.
10. Thorne BM, Aaron M, Latham EE. Effects of olfactory bulb ablation upon emotionality and muricidal behavior in four rat strains. J Comp Physiol Psychol 1973;84:339-44.
11. van Riezen H, Leonard BE. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 1990;47:21-34.
12. Song C, Earley B, Leonard BE. Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress? Ann N Y Acad Sci 1995;771:55-72.
13. Redmond AM, Kelly JP, Leonard BE. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997;58:355-9.
14. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997;74:299-316.
15. Hozumi S, Nakagawasai O, Tan-No K, et al. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav Brain Res 2003;138:9-15.
16. Song C, Killeen AA, Leonard BE. Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 1994;30:24-8.
17. Song C, Leonard BE. Interleukin-2-induced changes in behavioural, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat. Neuroimmunomodulation 1995;2:263-73.
18. Song C, Earley B, Leonard BE. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav Immun 1996;10:1-16.
19. Song C, Earley B, Leonard BE. Behavioural and immunological effects of the antihistamine terfenadine in olfactory bulbectomized rats. Eur Neuropsychopharmacol 1996;6:157-62.
20. Leonard BE, Song C. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol 2002;5:345-56.
21. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 2003;44:1984-91.
22. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005;29:627-47.
23. Butler J, Tannian M, Leonard BE. The chronic effects of desipramine and sertraline on platelet and synaptosomal 5HT uptake in olfactory bulbectomised rats. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:585-94.
24. Jesberger JA, Richardson JS. Effects of antidepressant drugs on the behavior of olfactory bulbectomized and sham-operated rats. Behav Neurosci 1986;100:256-74.
25. Komori T, Fujiwara R, Tanida M, Nomura J, Yokoyama MM. Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation 1995;2:174-80.
26. Connor TJ, Harkin A, Kelly JP, Leonard BE. Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 2000;7:27-35.
27. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189-93.
28. Engblom D, Ek M, Saha S, Ericsson-Dahlstrand A, Jakobsson PJ, Blomqvist A. Prostaglandins as inflammatory messengers across the blood-brain barrier. J Mol Med 2002;80:5-15.
29. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007;14:65-71.
30. Collantes-Estevez E, Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003;19:402-10.
31. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-4.
32. Beiske AG, Svensson E, Sandanger I, et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008;15:239-45.
33. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol 2006;253:219-23.
34. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002;159:1862-8.
35. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007;68:1596-602.
36. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-8.
37. Caballero J, Hitchcock M, Beversdorf D, Scharre D, Nahata M. Long-term effects of antidepressants on cognition in patients with Alzheimer's disease. J Clin Pharm Ther 2006;31:593-8.
38. McDonald WM, Holtzheimer PE, 3rd, Byrd EH. The diagnosis and treatment of depression in Parkinson's disease. Curr Treat Options Neurol 2006;8:245-55.
39. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-75.
40. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18:414-8.
41. Gorna K, Jaracz K, Wrzyszczynska L, Rybakowski F. Quality of life and depression in schizophrenic patients. Adv Med Sci 2007;52 Suppl 1:108-11.
42. Whalley HC, Mowatt L, Stanfield AC, et al. Hypofrontality in subjects at high genetic risk of schizophrenia with depressive symptoms. J Affect Disord 2007.
43. Zisook S, Montross L, Kasckow J, et al. Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia. Am J Geriatr Psychiatry 2007;15:1005-14.
44. Strous RD, Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 2006;6:54-60.
45. Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. Olfactory loss in multiple sclerosis. J Neurol Sci 1999;168:127-30.
46. Peters JM, Hummel T, Kratzsch T, Lotsch J, Skarke C, Frolich L. Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques. Am J Psychiatry 2003;160:1995-2002.
47. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-6.
48. Quagliato LB, Viana MA, Quagliato EM, Simis S. [Olfactory dysfunction in Parkinson's disease]. Arq Neuropsiquiatr 2007;65:647-52.
49. Corcoran C, Whitaker A, Coleman E, et al. Olfactory deficits, cognition and negative symptoms in early onset psychosis. Schizophr Res 2005;80:283-93.
50. Kopala LC, Good KP, Morrison K, Bassett AS, Alda M, Honer WG. Impaired olfactory identification in relatives of patients with familial schizophrenia. Am J Psychiatry 2001;158:1286-90.
51. Pause BM, Miranda A, Goder R, Aldenhoff JB, Ferstl R. Reduced olfactory performance in patients with major depression. J Psychiatr Res 2001;35:271-7.
52. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501-37.
53. Shovman O, Zandman-Goddard G, Gilburd B, et al. Restricted specificity of anti-ribosomal P antibodies to SLE patients in Israel. Clin Exp Rheumatol 2006;24:694-7.
54. Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007;6:119-25.
55. Shoenfeld Y. The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot. J Mol Med 2007;85:907-9.
56. Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005;38:85-92.
57. Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006;13:77-83.
58. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
59. Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005;14:571-5.
60. Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 2007;32:37-46.
61. Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:1053-5.
62. Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
63. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998;41:1819-27.
64. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000;59:99-104.
65. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus 1996;5:178-83.
66. Yoshio T, Masuyama J, Ikeda M, et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995;22:1681-7.
67. Shoenfeld Y. To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 2007;28:165-9.
68. Katzav A, Solodeev I, Brodsky O, et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007;56:938-48.
69. Blank M, Beinglass I, Shoenfeld Y. The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression. Expert Opin Biol Ther 2007;7:1283-5.
70. Matus S, Burgos PV, Bravo-Zehnder M, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007;204:3221--34.
71. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007;36:297-315.
72. Appenzeller S, Carnevalle AD, Li LM, Costallat LT, Cendes F. Hippocampal atrophy in systemic lupus erythematosus. Ann Rheum Dis 2006;65:1585-9.
73. Emmer BJ, van der Grond J, Steup-Beekman GM, Huizinga TW, van Buchem MA. Selective involvement of the amygdala in systemic lupus erythematosus. PLoS Med 2006;3:e499.